GHRS GH Research PLC
Company Analysis
Latest News
GH Research PLC Q2 2026 Earnings Preview: What Analysts Expect on August 06, 2026
GH Research is expected to report zero revenue and a consensus EPS loss of $0.31, with shares trading near $28.07 against a bullish average analyst price...
GH Research Gains Wells Fargo Support, Citing Undervalued Depression Drug
Wells Fargo initiated coverage of GH Research PLC (GHRS) with an Overweight rating. The investment bank set a price target of $44 for the stock. Analysts...
GH Research Rides a Wave of Depression-Drug Optimism — But Can a Pre-Revenue Biotech Justify the Hype Before Phase 3 Even Starts?
Shares of GH Research PLC surged 6.8% to $28.75 on July 16, buoyed by sustained investor enthusiasm around the Dublin-based biotech's approaching late-stage...
🟢 GH Research is trading 10.2% up
GH Research is trading at $29.66, up 10.2% from a comparison close of $26.92 during regular trading. This is a price-action follow-up, so a separate catalyst...
🟢 GH Research surges 8.1% on Eli Lilly-AtaiBeckley acquisition talks, analyst 'read-through'
• GH Research (GHRS) shares are trading up 8.1% today at $28.75, following reports of Eli Lilly's advanced negotiations to acquire psychedelic-medicine...
🟢 GH Research is trading 5.9% up today on clinical progress in depression treatments
GH Research is trading 5.9% up at $26.84 as investors react to continued clinical and regulatory progress for its depression treatments. • Shares are...
🔴 GH Research is trading 6% down today on biotech sector weakness and post-earnings pressure
GH Research is trading at approximately $25.00, down 6% today as the stock pulls back following a significant year-to-date rally. • The decline is driven by a...
🟢 GH Research PLC is trading 7.37% up in pre-market
GHRS is trading at $29.00, up 7.37% in pre-market.